
Annual report 2025
added 02-21-2026
Aurora Cannabis Net Income 2011-2026 | ACB
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aurora Cannabis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -695 M | -3.28 B | -291 M | 71.9 M | -13 M | -5.72 M | -9.52 M | -400 K | -393 K | -316 K | -322 K |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.9 M | -3.28 B | -384 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-13 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
-598 M | $ 1.19 | 3.48 % | $ 128 M | ||
|
China Pharma Holdings
CPHI
|
-4.74 M | $ 0.61 | -1.46 % | $ 10.7 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 3.9 | 1.56 % | $ 54.8 M | ||
|
Cronos Group
CRON
|
-73.1 M | $ 2.74 | 3.6 % | $ 1.43 B | ||
|
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | ||
|
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | ||
|
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
-760 M | $ 10.91 | -0.27 % | $ 559 M | ||
|
Harrow Health
HROW
|
-24.4 M | $ 52.51 | 1.86 % | $ 1.71 B | ||
|
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M | ||
|
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
-50.4 M | $ 4.3 | -0.69 % | $ 267 M | ||
|
OrganiGram Holdings
OGI
|
-131 M | $ 1.44 | 2.5 % | $ 402 M | ||
|
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | ||
|
Jupiter Wellness
JUPW
|
-49.4 M | - | - | $ 33.6 M | ||
|
Bausch Health Companies
BHC
|
-592 M | $ 6.04 | 0.83 % | $ 2.2 B | ||
|
Sundial Growers
SNDL
|
-230 M | $ 1.55 | 4.03 % | $ 3.37 M | ||
|
Neoleukin Therapeutics
NLTX
|
13.7 M | - | - | $ 193 M | ||
|
Pacira BioSciences
PCRX
|
-99.6 M | $ 23.39 | 1.21 % | $ 1.08 B | ||
|
Organogenesis Holdings
ORGO
|
861 K | $ 4.01 | 2.42 % | $ 528 M | ||
|
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
-172 M | $ 14.63 | 0.48 % | $ 2.01 B | ||
|
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
-8.44 M | $ 0.94 | 1.95 % | $ 21.9 M | ||
|
Relmada Therapeutics
RLMD
|
-98.8 M | $ 4.25 | 5.33 % | $ 128 M | ||
|
Tilray
TLRY
|
-1.45 B | $ 7.89 | 4.44 % | $ 4.88 B | ||
|
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
-332 M | $ 12.04 | - | $ 855 M | ||
|
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 2.83 | -0.35 % | $ 3.51 M | ||
|
Solid Biosciences
SLDB
|
-125 M | $ 6.17 | 5.11 % | $ 252 M | ||
|
SCYNEXIS
SCYX
|
67 M | $ 0.8 | 3.91 % | $ 38.3 M | ||
|
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
-37.8 M | $ 2.63 | 6.05 % | $ 355 M | ||
|
TherapeuticsMD
TXMD
|
-10.3 M | $ 2.25 | -1.32 % | $ 23.5 M | ||
|
cbdMD
YCBD
|
-153 K | $ 0.92 | 0.72 % | $ 3.97 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | ||
|
Viatris
VTRS
|
2.08 B | $ 16.15 | 1.22 % | $ 19.6 B |